Study title: A multi-centre, randomised, open-label, parallel group clinical trial to assess the efficacy and safety of Salmeterol/Fluticasone Propionate combination product (2x 25/125μg/actuation, bd) via a hydrofluoroalkane metereddose inhaler compared with Salmeterol/Fluticasone Propionate Accuhaler™ (50/250μg bd) in adult Chinese patients with mild to moderate asthma.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Respiratory Tract Diseases [C08] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: FLUTICASONE AND SALMETEROL | |||||
| ATC code: | |||||
| Document link: Fluticasone-Propionate-Sameterol-SAS30021-ICHE3.pdf | |||||
| Document date: 2011-09-30 | |||||
| Study number: SAS30021 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |